VERZENIO

उत्पाद अवलोकन

About VERZENIO

VERZENIO is a prescription medication containing the active ingredient abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. It is used in the treatment of certain types of breast cancer, specifically hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and metastatic breast cancer.

Key Benefits & Uses

• Treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and metastatic breast cancer
• Delaying disease progression and improving overall survival in patients with HR+, HER2-, and metastatic breast cancer
• Combination therapy with endocrine therapy for the treatment of HR+, HER2-, and locally advanced or metastatic breast cancer

Active Ingredient & Action

Abemaciclib works by inhibiting the activity of CDK4 and CDK6, enzymes that play a crucial role in cell division. By blocking these enzymes, abemaciclib prevents the growth and proliferation of cancer cells, ultimately slowing down disease progression.

Important Notes

VERZENIO is a prescription medication and should only be used under the guidance of a healthcare professional. It is essential to discuss the potential benefits and risks of VERZENIO with your doctor before starting treatment. Common side effects may include diarrhea, nausea, fatigue, and neutropenia. Patients should be monitored regularly for signs of adverse reactions and adjust their treatment plan as necessary.